Pros | ![]() Beats FD returns for both 3Y & 5Y duration. | |||
Cons | ![]() 5Y returns in the bottom 25% of the category. |
INDMoney rank | 3/8 | |||
Category,Subcateogry | Equity,Sector - Healthcare | |||
Fund Age | 9 Years | |||
Fund Size | 1184 Cr | |||
Min Investment | SIP ₹100 Lumpsum ₹5000 | |||
Expense Ratio | 0.72% | |||
Exit Load | 0.25% | |||
Benchmark Index | Nifty Pharma TR INR |
No of Holdings | 41 | |||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.79%) Aurobindo Pharma Ltd (7.27%) Cipla Ltd (5.97%) Apollo Hospitals Enterprise Ltd (5.66%) Lupin Ltd (5.2%) | |||
No of Sectors | 2 | |||
Top 3 Sectors | Health (97.56%) Basic Materials (2.44%) | |||
Equity % | 95.76% | |||
Debt % | - | |||
P/E | 34.41 | |||
P/B | 4.98 | |||
Credit Quality | - | |||
Modified Duration | - | |||
YTM | - |
1-Month Return | 4.99% | |||
3-Month Return | -3.75% | |||
6-Month Return | -8.15% | |||
1-Year Return | 17.07% | |||
3-Year Return | 20.02% | |||
5-Year Return | 23.79% |
Sharpe | 0.81 | |||
Alpha | 3.47 | |||
Beta | 0.95 | |||
Standard Deviation | 16.85 | |||
Information Ratio | 1.13 |
Description | Tata India Pharma & Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | |||
Managers | Meeta Shetty |